Transcriptome differences in adipose stromal cells derived from pre- and postmenopausal women

Yun Xie 1†, Bin Fang 1†, Wenhui Liu 2‡, Guangshuai Li 2, Ru-Lin Huang 1, Lu Zhang 1, Jiahao He 1, Shuangbai Zhou 1, Kai Liu 1 and Qingfeng Li 1

Abstract

Background: As the population ages, an increasing number of postmenopausal women are donors of adipose stromal cells (ASCs) and may benefit from autologous ASC-related treatments. However, the effect of menopausal status on ASCs has not been investigated.

Methods: RNA sequencing data were downloaded, and differentially expressed genes (DEGs) were identified. Hierarchical clustering, Gene Ontology, and pathway analyses were applied to the DEGs. Two gene coexpression network analysis approaches were applied to the DEGs to provide a holistic view and preserve gene interactions. Hub genes of the gene coexpression network were identified, and their expression profiles were examined with clinical samples. ASCs from pre- and postmenopausal women were co-cultured with monocytes and T cells to determine their immunoregulatory role.

Results: In total, 2299 DEGs were identified and presented distinct expression profiles between pre- and postmenopausal women. Gene Ontology and pathway analyses revealed some fertility-, sex hormone-, immune-, aging-, and angiogenesis-related terms and pathways. Gene coexpression networks were constructed, and the top hub genes, including TIE1, ANGPT2, RNASE1, PLVAP, CA2, and MPZL2, were consistent between the two approaches. Expression profiles of hub genes from the RNA sequencing data and clinical samples were consistent. ASCs from postmenopausal women elicit M1 polarization, while their counterparts facilitate CD3/4+ T cell proliferation.

Conclusions: The present study reveals the transcriptome differences in ASCs derived from pre- and postmenopausal women and provides holistic views by preserving gene interactions via gene coexpression network analysis. The top hub genes identified by this study could serve as potential targets to enhance the therapeutic potential of ASCs.

Keywords: Adipose stromal cells, Premenopausal, Postmenopausal, Transcriptome, Immunoregulation

Background

Adipose stromal cells (ASCs) are a group of mesenchymal stromal cells routinely isolated from the stromal vascular fraction of adipose tissue. In addition to preserving the main characteristics of mesenchymal stromal cells, ASCs are also distinguished by their high abundance and easy access [1], which makes them very...
promising candidates in numerous clinical trials targeting cardiac, immunological, rheumatological, and many other diseases [2]. One frequently used method to obtain ASCs is liposuction [3, 4]. It has been shown that donor traits such as age, body mass index, gender, donor site, and menopausal status impact ASC viability and function during liposuction [5]. Among these factors, menopausal status may be an important characteristic that interacts with aging, hormonal status, and many other factors. However, the effects of menopausal status on ASCs have not been thoroughly investigated.

Some studies provide an indirect profile of the relationship between menopausal status and ASCs by focusing on aging and sex hormones. Aging has been reported to impair the proliferation, differentiation, and angiogenic capacity of ASCs [6–9]. Estrogen has long been recognized as able to regulate ASC proliferation, migration, and differentiation [10], while ASCs have been shown to affect ovary function. Sun et al. found that topical or systematical application of ASCs could improve mouse ovary function in a chemotherapy-induced ovary failure model [11]. Unlike ASCs, the relationship between bone marrow mesenchymal stromal cells and menopausal status has been preliminarily investigated by Liu and his colleagues [12]. They found that bone marrow mesenchymal stromal cells derived from pre- and postmenopausal rats have different characteristics. These studies are very inspiring, as direct data focused on the effects of menopausal status on ASCs are still lacking.

As the population ages, an increasing number of postmenopausal women may desire liposuction, which is one of the most important sources of ASCs. These women may also benefit from autologous ASC-related treatments. Thus, we need to determine the effect of menopausal status on ASCs. The present study focuses on the transcriptome differences associated with ASCs derived from pre- and postmenopausal women and annotates the changes with integrated bioinformatics approaches. We also applied Weighted Gene Coexpression Network Analysis (WGCNA) and Multiscale Embedded Gene Coexpression Network Analysis (MEGENA) to reveal gene interaction networks and identify the key players in ASCs pre- and postmenopause. These hub genes may be targets to enhance the therapeutic potential of ASCs pre- and postmenopause. These hub genes may also benefit from autologous ASC-related treatments.

Materials and methods

Data acquisition and raw data processing

RNA sequencing data were downloaded from the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus [13] under accession number GSE86244, which was provided by Shan et al. [14]. We only selected ASC data from women < 45 years old (12 patients in the premenopause group) and ≥ 55 years old (3 patients in the postmenopause group). All ASCs were isolated from adipose tissue harvested during elective abdominoplasty. Raw data were transformed with the fastq-dump software included in the NCBI SRA Toolkit (www.ncbi.nlm.nih.gov/sra). Quality control was performed with FastQC (www.bioinformatics.babraham.ac.uk/projects/fastqc/), and the data quality looked quite good. Thus, we skipped the data trimming process. The reads were then aligned against the GRCh38 reference genome downloaded from Ensembl [15] with hisat2 [16]. Transcripts were assembled with StringTie [17], and differentially expressed genes (DEGs) were identified by DESeq2 [18] by comparing the genes in postmenopausal women to premenopausal women. DEGs were determined as those with a p value less than 0.05 and no further filtering with an adjusted p value and fold change to keep potential meaningful genes as much as possible at the cost of increasing the computational burden of downstream analysis.

Annotation of DEGs

To provide an overview of the DEGs, we applied hierarchical clustering analysis using MeV [19]. MeV generated a dendrogram aligned with a heat map that could be used to check whether DEGs were present in distinct expression profiles between pre- and postmenopausal women.

To provide a complete picture of the changes associated with menopause, we applied Gene Ontology (GO) and pathway analyses to annotate the DEGs. GO includes three structured ontologies that describe gene products in terms of their associated biological processes, cellular components, and molecular functions in a species-independent manner [20, 21]. GO analysis is an enrichment analysis that determines which GO terms are overrepresented or underrepresented for a given set of genes. Upregulated and downregulated genes were analyzed separately. GO analysis can be performed by many means; we chose GOSlimViewer [22] to provide a high-level summary of the GO terms using a Generic GO slim set. According to the Gene Ontology Consortium, GO slims are filtered versions of GO ontologies that contain a subset of the terms from the complete GO and offer a broad overview of the ontology content.

Pathway analysis was achieved with the Database for Annotation, Visualization and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov/) [23] by interrogating the Kyoto Encyclopedia of Genes and Genomes (KEGG) database [24]. Upregulated and downregulated genes were analyzed separately. KEGG is a canonical pathway analysis method and is well recognized by the scientific
community. However, as reviewed in [25], KEGG, as an over-representation analysis, only considers the number of genes alone and ignores any values associated with them. Thus, the DEG information was not fully exploited. We then used the Ingenuity Pathway Analysis Database (IPA, www.ingenuity.com), which considers the DEG fold changes and p values as a supplement, and all the DEGs were analyzed together. The combination of KEGG and IPA provided integrated and precise pathway analysis results for the DEGs.

**Gene coexpression network analysis**

After identification of the DEGs, a common procedure is the double filtration of DEGs based on their fold change and p value [26]. Highly ranked DEGs could serve important biological functions and are usually selected for downstream analysis. However, biological processes are usually cascade-like. Thus, downstream genes usually rank higher than upstream genes when applying double filtration, and gene interactions are often neglected when focusing on individual DEGs alone. Therefore, we also applied WGCNA and MEGENA to reveal gene interaction networks and identify the key players in ASCs pre- and postmenopause. To reduce the noise and preserve the main fluctuations in the genes, only DEGs were used in the gene coexpression network analysis; this was the basic and very first analysis step in the transcriptomic analysis procedure [27].

WGCNA was performed with the WGCNA package [28] in the static programming language and environment R [29]. WGCNA is distinguished as embracing the idea that gene networks follow a scale-free distribution pattern similar to many other biological networks [30]. First, a gene correlation matrix was transformed into a scale-free network. Second, a dynamic tree-cutting algorithm [31] was applied to perform unsupervised hierarchical clustering, and the clustering tree branches were defined as modules. Third, correlations between the modules and menopausal status were calculated, and a highly related module was selected. Module eigengenes, which are principal components of gene expression profiles, were selected as representatives for each module in this step, and menopausal status was defined as a binary variable. Fourth, hub genes in the selected module were sorted by ranking their intra-modular connectivity and correlation with the module eigengenes. Hub genes are the backbones of scale-free networks [32] and have been found to be biologically meaningful in many diseases [33–35].

MEGENA was performed with the MEGENA package [36] in R. Unlike WGCNA, MEGENA preserves gene interaction by beginning with Fast Planar Filtered Network Construction. Genes in this Planar Filtered Network (PFN) were then clustered by Multiscale Clustering Analysis. Hub genes from each cluster at each scale were then identified by Multiscale Hub Analysis. The developers of MEGENA suggest that the multiscale hub genes tend to be biologically meaningful [36]. MEGENA revealed meaningful multi-scale organizations of gene coexpression networks, which could be a good supplement to WGCNA. The hub genes identified by these two methods were also compared. We applied Gephi [37] to visualize the Weighted Gene Coexpression Network (WGCN) and Multiscale Embedded Gene Coexpression Network (MEGCN) with a Fruchterman-Reingold layout.

To check whether the selected module in WGCN and the multiscale hub genes in MEGCN are highly related to menopausal factors, we also annotated these genes. GO analysis, like KEGG, is a kind of over-representation analysis method that only considers the number of genes and ignores their values [25]. Thus, up- and downregulated genes should not be analyzed together with GO analysis, as they represent opposite tendencies. We scrutinized these genes and found that they were composed of both up- and downregulated genes. Therefore, GO analysis was not applicable, and IPA was applied.

**Conformation of hub gene expression**

This study was approved by the Institutional Ethics Committee of Shanghai Ninth People’s Hospital. ASCs were isolated from subcutaneous adipose tissues of ten healthy donors who underwent abdominal liposuction after providing informed consent. Among these clinical samples, five patients were premenopausal women with an average age of 27.3, and five patients were postmenopausal women with an average age of 73.8.

We also performed immunophenotypic analysis and multipotent induction of ASCs.

The expression of the top hub genes, including TIE1, ANGPT2, RNAE1, PLVAP, CA2, and MPZL2, was verified with clinical samples by real-time polymerase chain reaction (RT-PCR). The primers used in this study are shown in Supplementary File 7. The housekeeping gene GAPDH was used for normalization. Significant differences among groups were assessed using the two-tailed Student’s t test. p < 0.05 was considered statistically significant. The results are presented as the mean ± S.D.

**Immunoregulatory role of ASCs from pre- and postmenopausal women**

Many immune system-related GO terms and pathways were identified in the present study. Therefore, co-cultured ASCs with the human leukemia monocytic cell lines THP-1 and CD3/4+ T cells to determine the immunoregulatory role of ASCs from pre- and postmenopausal women. The mRNA expression of iNOS and Arg-1 (markers for M1 and M2 macrophages) was
analyzed in THP-1 cells to determine the polarization of macrophages. The Alamar Blue assay and cell cycle analysis were performed for CD3/4+ T cells to determine the proliferation difference.

**Results**

**Characteristics and annotation of the DEGs**

In total, 2299 genes were differentially expressed in the pre- and postmenopausal women. Among them, 794 genes were upregulated and 1505 genes were downregulated. A complete list of the identified genes is provided in Supplementary File 1. Hierarchical cluster analysis with MeV indicated that DEGs presented distinct expression profiles between pre- and postmenopausal women (Fig. 1). Pre- and postmenopausal women were clustered into two clusters. Only part of the hierarchical cluster results is shown for clarity, and the complete results are provided in Supplementary File 2.

GO analysis with GOSlimViewer revealed many basic biological processes that were altered pre- and postmenopause (Supplementary File 3), indicating that these DEGs participate in various biological processes. It is not surprising that the GO slim term Reproduction and Embryo Development was found for both up- and downregulated DEGs, indicating that the recession of fertility in postmenopausal women is reflected in ASCs. Two related terms, Anatomical Structure Development and Anatomical Structure Formation Involved in Morphogenesis, were also found. The slim term Ageing was also identified among the downregulated DEGs (Supplementary File 3). Immune System Process was found for both the up- and downregulated DEGs.

The pathway analysis results are shown in Table 1; only related pathways are listed, and the complete pathway analysis results are given in Supplementary File 4. The identification of oocyte meiosis, GNRH signaling, and relaxin signaling indicates that sex hormone- and fertility-related alterations are preserved among the DEGs to some extent. Immune and angiogenesis pathways were also identified.

**Gene coexpression network analysis**

Canonical analysis methods focus on individual DEGs with high fold changes and a small p value, similar to those at the top left and right corners in the DEG volcano plot (Fig. 2a). However, a holistic view is not generated if we ignore interactions between genes. Thus, we applied WGCNA and MEGENA for these DEGs. WGCNA identified four modules within DEGs that we described as turquoise, yellow, blue, and brown (Fig. 2b).
DEGs that could not be clustered into any specific modules were classified into a grey module. As shown in Fig. 2c, the yellow module is the most related to menopause status, with the highest absolute value correlation coefficient (−0.78) and lowest p value (7e−04). The visual representation of the WGCN is shown in Fig. 2d, and a summary of the WGCN is provided in Supplementary File 5. As shown in Fig. 2d, genes belonging to the same module tend to be close to one another. The top 10 hub genes in the yellow module are TIE1, ANGPT2, PLVAP, CA2, RNASE1, MPZL2, SELE, SOX17, YBX1P6, and PPP1R16B, which were identified by ranking their intra-modular connectivity. Readers can refer to Supplementary File 5 for further details.

MEGENA identified 83 modules and 427 hub genes using three scales. Among the hub genes, 87 were hub genes in all three scales. The visual representation of MEGCN is given in Fig. 3. As shown in Fig. 3, genes belonging to the same module are usually clustered together. The complete MEGCN is summarized in Supplementary File 6, including information about the multiscale hub genes. By comparing the top hub genes in the WGCN yellow module with the multiscale hub genes in MEGCN, we found that 5 of the top 6 hub

---

**Table 1** Pathway analysis of DEGs

| Pathway                                      | -log (p value) |
|----------------------------------------------|----------------|
| KEGG-up                                      |                |
| Leukocyte transendothelial migration         | 3.40           |
| Platelet activation                          | 3.00           |
| Oocyte meiosis                               | 2.16           |
| Vascular smooth muscle contraction           | 1.90           |
| Endometrial cancer                           | 1.37           |
| Prostate cancer                              | 1.36           |
| IPA                                          |                |
| IL-8 signaling                               | 2.22           |
| Leukocyte extravasation signaling            | 1.70           |
| TGF-β signaling                              | 1.56           |
| Inhibition of angiogenesis by TSP1           | 1.54           |
| Nitric oxide signaling in the cardiovascular system | 1.52           |
| Corticotropin-releasing hormone signaling    | 1.49           |
| GNRH signaling                               | 1.47           |
| CXCR4 signaling                              | 1.43           |
| Relaxin signaling                            | 1.41           |

---

**Fig. 2** a Volcano plot of DEGs. The horizontal axis represents the logarithmic fold change, and the vertical axis shows the -log (p value) of the DEGs. b Hierarchical clustering of the WGCN. Each line in the hierarchical cluster tree represents a gene, and the distance between two genes in the WGCN is shown as the height on the vertical axis. The color bar beneath shows the module membership for each gene. c The module-trait relationships in the WGCN. Each cell represents a module with the module name and corresponding color at the left. The numbers near the cells are the correlation coefficient (upper) and corresponding p value (lower). d Visual representation of the WGCN. Each node represents a gene, and the color indicates module membership. Node size is proportional to the intra-modular connectivity. Edges between nodes represent interactions between genes, and darker edges indicate a higher correlation. The names of the top 6 hub genes are given in the yellow module.
genes in the yellow module were also hub genes in all three scales in MEGCN. These 5 hub genes are TIE1, ANGPT2, PLVAP, CA2, and MPZL2. RNASE1, the last of the top 6 hub genes, was a hub gene in two scales in MEGCN. This consistency of the hub genes in WGCNA and MEGENA could support their authenticity to some extent. The identification of hub genes with these two methods is quite consistent.

We also applied IPA to examine whether the yellow module and multiscale hub genes are highly related to menopausal status. Some highly related pathways are shown in Table 2. Most pathways are either immune- or angiogenesis-related. Sex hormone-related pathways were also identified, such as GNRH signaling, relaxin signaling, and androgen signaling. It should be noted that the $p$ value for androgen signaling is slightly greater than 0.05.

**Conformation of hub gene expression**

hASCs were isolated and confirmed positive for CD73, CD90, and CD105 and negative for CD34, CD45, and HLA-DR according to flow cytometry analysis of stromal cell-related surface markers (Supplementary File 8). The ability of the generated hASC cultures to differentiate into multiple cell types was confirmed by using oil red O staining for lipid droplet formation, alizarin red S staining for calcium deposition formation, and Alcian blue staining for sulfated proteoglycan formation (Supplementary File 9). The expression of the top hub genes, including TIE1, ANGPT2, RNASE1, PLVAP, CA2, and MPZL2, was verified by RT-PCR. The postmenopausal clinical sample group possessed higher expression levels of TIE1, ANGPT2, RNASE1, PLVAP, CA2, and MPZL2 (Fig. 4), which agreed with the RNA sequencing data.

**Immunoregulatory role of ASCs from pre- and postmenopausal women**

THP-1 cells co-cultured with ASCs derived from postmenopausal women expressed more iNOS and less Arg-1 than their counterparts (Fig. 5a–c), indicating that ASCs derived from postmenopausal women are inclined to elicit macrophage M1 polarization. CD3/4+ T cells co-cultured with ASCs derived from premenopausal women exhibited increased proliferation activity (Fig. 5d), while those co-cultured with ASCs derived from postmenopausal women showed G2/M arrest (Fig. 5e, f).
Discussion

As the population ages, postmenopausal women are becoming a more important source of ASCs, and there is an increasing demand for ASC-related treatments for postmenopausal women. Therefore, the transcriptome differences between ASCs derived from pre- and postmenopausal women should be identified. The present study identified DEGs between pre- and postmenopausal women and applied integrated annotation methods to annotate them. We also applied two gene coexpression network analysis approaches to identify gene networks and hub genes from ASCs derived from pre- and postmenopausal women. A holistic view was generated by preserving gene interactions, which helps deepen our understanding of ASCs.

Pre- and postmenopausal women were clustered into two clusters in the DEG hierarchical cluster analysis, indicating that ASCs derived from pre- and postmenopausal women may be quite different at the transcriptome level. GO and pathway analyses provided a snapshot of the genetic variance between pre- and postmenopausal women and revealed some fertility-, sex hormone-, immune-, aging-, and angiogenesis-related terms or pathways. Pathway analysis was applied to the yellow module and multiscale hub genes and found that they share immune-, angiogenesis-, and sex hormone-related pathways. We also noticed a high consistency among the top hub genes in the yellow module and the multiscale hub genes in MEGCN. These top hub genes included TIE1, ANGPT2, RNASE1, PLVAP, CA2, and

Table 2 Ingenuity pathway analysis of the yellow module and multiscale hub genes

| Pathway                                                              | -log (p value) |
|----------------------------------------------------------------------|----------------|
| **Yellow module**                                                     |                |
| Agranulocyte adhesion and diapedesis                                  | 4.15           |
| Granulocyte adhesion and diapedesis                                   | 3.13           |
| Th2 pathway                                                          | 2.25           |
| Wnt/β-catenin signaling                                              | 2.08           |
| Th1 and Th2 activation pathway                                        | 2.00           |
| IL-8 signaling                                                       | 1.90           |
| Angiopoietin signaling                                               | 1.81           |
| VEGF family ligand-receptor interactions                             | 1.70           |
| VEGF signaling                                                       | 1.60           |
| Nitric oxide signaling in the cardiovascular system                  | 1.54           |
| PTEN signaling                                                       | 1.46           |
| **Multiscale hub genes**                                             |                |
| IL-8 signaling                                                       | 3.30           |
| GNRH signaling                                                       | 2.90           |
| Angiopoietin signaling                                               | 2.66           |
| Cardiac β-adrenergic signaling                                       | 1.95           |
| Relaxin signaling                                                    | 1.83           |
| CXCR4 signaling                                                      | 1.76           |
| Breast cancer regulation by Stathmin1                                | 1.51           |
| IL-1 signaling                                                       | 1.42           |
| Androgen signaling                                                   | 1.28           |

Fig. 4 Confirmation of hub gene expression. The relative expression of TIE1, ANGPT2, RNASE1, PLVAP, CA2, and MPZL2 in RNA-seq and clinical samples. *p < 0.05, **p < 0.01, and ***p < 0.001 vs premenopausal RNA-seq or clinical samples. The expression profile of the top hub genes agreed between the RNA sequencing data and clinical samples.
MPZL2. Their consistency could support the authenticity of WGCNA and MEGENA to some extent. The expression of some top hub genes has also been verified with clinical samples.

In addition to pure bioinformatics analysis, we also performed functional assays to identify the immunoregulation difference in ASCs from pre- and postmenopausal women. We found that ASCs from postmenopausal women could induce M1 polarization of macrophages, while their counterparts facilitate CD3/4+ T cell proliferation. These results are consistent with our GO and pathway analysis. However, these results are quite preliminary, and more work is needed to determine the mechanism.

Unlike bone marrow mesenchymal stromal cells [12], the relationships between ASCs and menopausal status have never before been researched. Although some studies have investigated the role of aging and sex hormones on ASCs, the present study is different from them. Several studies have determined the negative role of age on ASCs, such as those described by Monika et al. [38] and Ma et al. [39]. These studies not only deepen our understanding of ASCs but also instruct the clinical application of ASCs. Regrettably, their aging criteria are inconsistent, and this is a major problem that similar studies have faced. Menopause, to some extent, could be seen as aging with explicit criteria, which is the reason many aging-related results were identified in the present study. For sex hormones, the situation is similar. The present study found that ASCs derived from pre- and postmenopausal women are not equivalent, at least not at the transcriptome level. Thus, more attention should be paid when applying ASCs derived from postmenopausal women. Moreover, approaches to enhance the function of ASCs may also be needed.

Liang et al. proposed that genetic modification of pivotal genes might alter the paracrine profile and maximize the therapeutic potential of mesenchymal stromal cells [40]. Many preconditioning approaches have been applied to improve the function of ASCs, such as epidermal growth factor and basic fibroblast growth factor [41], vascular endothelial growth factor (VEGF) [42], and many other factors [43]. The top hub genes identified in the present study could serve as potential targets, as they are not only key players in the gene coexpression network but also have important functions.
Some top hub genes may affect vascular homeostasis. TIE1 [44], ANGPT2 [45], and PLVAP [46] all interact with VEGF. TIE1 was reported to control angiogenesis and vascular remodeling [47, 48]. Failure to establish the structural integrity of vascular endothelial cells has been found in embryos deficient in TIE1 [49]. ANGPT2 was reported to promote angiogenesis by destabilizing blood vessels under the regulation of VEGF [50, 51]. Specifically, ANGPT2 is associated with follicular growth and angiogenesis during the preovulatory period in premenopausal women [52]. PLVAP could regulate angiogenesis and vascular permeability [53, 54]. RNASE1, though not specifically related to VEGF yet, encodes a member of the ribonuclease A superfamily, which is an important member in angiogenin [55]. As extracellular RNA in the vascular system can enhance coagulation and permeability, RNASE1 could maintain vascular homeostasis by regulating extracellular RNA [56].

Some top hub genes may also participate in immunomodulation. ANGPT2 can recruit monocytes [57, 58], which results in suppressing T cell activation [59]. MPZL2 could regulate the development of the thymus and T cell function [60, 61]. As mentioned above, PLVAP can regulate vascular permeability. Thus, it is not surprising that PLVAP was reported to mediate leukocyte transendothelial migration [62].

In addition to vascular homeostasis and immunomodulation, these top hub genes also have other related functions. ANGPT2 can enhance osteogenic differentiation and angiogenesis in bone marrow stem cells [63]. Therefore, alteration of the ANGPT2 expression profile may affect ASC differentiation. MPZL2 was found to maintain the pluripotency and self-renewal of glioblastoma-initiating cells [64]. Therefore, MPZL2 could play a role in maintaining the stemness of ASCs. CA2 is regulated by estrogen and androgens [65, 66] and plays a major role in osteoclast differentiation and bone resorption [67]. Zheng et al. found that ovariectomy results in the upregulation of CA2, which could be reversed by administration of 17 beta-estradiol [67]. They proposed that CA2 may be a target of estrogen’s protective role in bone loss. Therefore, upregulation of CA2 in ASCs may participate in bone loss in postmenopausal women, and targeting CA2 may improve the function of ASCs harvested from postmenopausal women.

One limitation of the present study is that all ASCs were isolated from adipose tissue harvested by abdominoplasty. ASCs from different donor sites may have different characteristics. For example, Cox-York and her colleagues found that estradiol, a type of estrogen, has region-specific effects on ASCs in postmenopausal women [68]. Therefore, ASCs from other anatomical sites may have different transcriptomic landscapes in postmenopausal women. However, menopause promotes systematc and extensive changes such as metabolic abnormalities and body fat re-distribution [69, 70]. Consequently, transcriptomic differences in ASCs at other anatomical sites are expected.

Conclusions
In conclusion, the present study revealed the transcriptome differences in adipose stem cells derived from pre- and postmenopausal women and provides holistic views by preserving gene interactions with gene coexpression network analyses. The top hub genes identified by the present study could serve as potential targets to enhance the therapeutic potential of ASCs.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13287-020-01613-x.

Additional file 1. A complete list of the identified genes differentially expressed in the pre- and postmenopausal women.
Additional file 2. The complete hierarchical cluster results of pre- and postmenopausal women.
Additional file 3. The slim term Ageing identified among the downregulated DEGs.
Additional file 4. Complete pathway analysis results.
Additional file 5. A summary of the WGCN.
Additional file 6. The complete WGCN.
Additional file 7. Primers used in this study.
Additional file 8. Immunophenotypic analysis of ASCs.
Additional file 9. Multipotent induction of ASCs.

Abbreviations
ANGPT2: Angiopoietin 2; ASCs: Adipose stromal cells; CA2: Carbonic anhydrase 2; DEGs: Differentially expressed genes; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; MEGENA: Multiscale Embedded Gene Coexpression Network; MEGCN: Multiscale Embedded Gene Coexpression Network Analysis; MPZL2: Myelin protein zero-like 2; NCBI: National Center for Biotechnology Information; PFN: Planar Filtered Network; PLVAP: Plasmalemma vesicle-associated protein; RNASE1: Ribonuclease A family member 1; RT-PCR: Real-time polymerase chain reaction; TIE1: Tyrosine kinase with immunoglobulin-like and EGF-like domains 1; WGCN: Weighted Gene Coexpression Network; WGCNA: Weighted Gene Coexpression Network Analysis.

Acknowledgements
We would like to thank Dr. Wei Ling, Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, for providing subcutaneous adipose tissues of postmenopausal female patients.

Authors’ contributions
YX contributed to the conception and design, financial support, and final approval of manuscript. BF contributed to the collection and assembly of data and manuscript critiquing and modification. WL contributed to the data analysis and interpretation and manuscript writing. GL contributed to the manuscript critiquing and modification. RH contributed to the provision of patients. LZ contributed to the provision of study material. JH contributed to the collection and assembly of data. SZ contributed to the provision of patients. KL contributed to the administrative support. QL contributed to the administrative support. All authors read and approved the final manuscript.
Funding
This work was supported by grants from the National Natural Science Foundation of China (No: 81701917), the Natural Science Foundation of Shanghai (No: 17ZR146500), the Shanghai Pujiang Program (No: 2019JD024), the Two-hundred Talent Program of Shanghai Jiao Tong University School of Medicine (No: 20191916), and the Clinical Research Program of 9th People’s Hospital of Shanghai affiliated to Shanghai Jiao Tong University School of Medicine (No: JYL004).

Availability of data and materials
The datasets supporting the conclusions of this article are included within the article (and its additional files).

Ethics approval and consent to participate
The use of human adipose tissue was approved by the Ethics Committee of Shanghai Ninth People’s Hospital. We obtained written informed consent from all the patients who participated in this study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 11 September 2019 Revised: 2 January 2020
Accepted: 19 February 2020 Published online: 28 February 2020

References
1. Zuk PA. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2001;12:479–95.
2. Toyserkani NM, Jørgensen MG, Tabatabaieefar S, Jensen CH, Sheikh SP, Serensen JA. Concise review: a safety assessment of adipose-derived cell therapy in clinical trials: a systematic review of reported adverse events. Stem Cells Transl Med. 2017;6:1786–94.
3. Aust L, Devlin B, Foster SJ, Halvorsen YDC, Hicok K, du Laney T, et al. Yield of human adipose-derived adult stem cells from liposuction aspirates. Cytotherapy. 2009;11(4):57–64.
4. Ailhaud G, Attar S, Dehkhoda A, Marcelli S, Martin R. Systematic review of patient factors affecting adipose stem cell viability and function: implications for regenerative therapy. Stem Cell Res Ther. 2017;8:45.
5. Almazan F, Neff RM, La Rosa JL, Adel SP, Brown GM, et al. The role of adipose tissue-derived stem cells. Annu Rev Med. 2008;59:58–44.
6. Alt EU, Senft C, Murthy SN, Slakey DP, Dunlop CL, Chaffin AE, et al. Aging alters tissue resident mesenchymal stem cell properties. Stem Cell Res. 2012;8:215–25.
7. Madonna R, Renna FV, Cellini C, Cotellese R, Picardi N, Francomano F, et al. Age-dependent impairment of number and angiogenic potential of adipose-derived stem cells. J Transl Med. 2016;14:126.
8. Varghese J, Griffin M, Mosadhe A, Butler P. Systematic review of patient factors affecting adipose stem cell viability and function: implications for regenerative therapy. Stem Cell Res Ther. 2017;8:45.
9. Schipper BM, Marra KG, Donnenberg AD, Rubin JP. Regional anatomic and age effects on cell function of human adipose-derived stem cells. Ann Plast Surg. 2008;60:38–44.
10. Ailhaud G, Attar S, Murthy SN, Slakey DP, Dunlop CL, Chaffin AE, et al. Aging alters tissue resident mesenchymal stem cell properties. Stem Cell Res. 2012;8:215–25.
11. Madonna R, Renna FV, Cellini C, Cotellese R, Picardi N, Francomano F, et al. Age-dependent impairment of number and angiogenic potential of adipose tissue-derived progenitor cells. Eur J Clin Invest. 2011;41:126–33.
12. Choudhry MS, Badowski M, Muise A, Pierce J, Harris DT. Donor age
13. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets - update. Nucleic Acids Res. 2013;41:D991–5.
14. Shan X, Roberts C, Kim EJ, Brenner A, Grant G, Percec V. Transcriptional and cell cycle alterations mark aging of primary human adipose-derived stem cells. Stem Cells. 2017;35:1592–401.
15. Kersey PJ, Allen JE, Armean I, Boddu S, Bolt BJ, Carvalho-Silva D, et al. Ensembl Genomes 2016: more genomes, more complexity. Nucleic Acids Res. 2016;44:D574–80.
16. Kim D, Perteza G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14:R36.
17. Perteza M, Perteza GM, Antonescu CM, Chang TC, Mendell JT, Salzberg SL. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol. 2015;33:290–5.
18. Perteza M, Kim D, Perteza GM, Leek JT, Salzberg SL. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Protoc. 2016;11:1650–67.
19. Wang YE, Kutnokov L, Pantensky A, Farid J, Quackenbush J. WebMW: a cloud platform for analyzing and visualizing cancer genomic data. Cancer Res. 2017;77:e11–4.
20. Blake JA, Christie KR, Dolan ME, Drabkin HJ, Hill DP, Ni L, et al. Gene ontology consortium: going forward. Nucleic Acids Res. 2015;43:D1049–56.
21. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. Nat Genet. 2000;25:25–9.
22. McCarthy FM, Bridges SM, Wang N, Magee GB, Williams WP, Luthe DS, et al. AgBase: a unified resource for functional analysis in agriculture. Nucleic Acids Res. 2007;35:D599–603.
23. Huang DW, Lempicki RA, Sherman BT. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57.
24. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. REGGe: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45:D353–61.
25. Khati P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches and outstanding challenges. Ouzounis CA, editor. PLoS Comput Biol. 2012;8:e1002375.
26. Zhang S, Cao J. A close examination of double filtering with fold change and T test in microarray analysis. BMC Bioinformatics. 2009;10:402.
27. Li L, Li YY, Li YY. Differential regulatory analysis based on coexpression network in cancer research. Biomed Res Int. 2016;2016:1–8.
28. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.
29. R Core Team. R: a language and environment for statistical computing. Vienna, 2017. https://cran-project.org/doc/FAQ-R/FAQ.html#Citing-R.
30. Barabasi AL. Scale-free networks: a decade and beyond. Science. 2009;325:412–3.
31. Langfelder P, Zhang B, Horvath S. Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package. BMC Bioinformatics. 2008;24:719–20.
32. Ghazalpour A, Doss S, Zhang B, Wang S, Plaisier C, Castellanos R, et al. Integrating genetic and network analysis to characterize genes related to mouse weight. PLoS Genet. 2006;2:1182–92.
33. Liu X, Hu A-X, Zhao J-L, Chen F-L. Identification of key gene modules in human osteosarcoma by co-expression analysis weighted gene co-expression network analysis (WGCNA). J Cell Biochem. 2017;118:3953–9.
34. Wan Q, Tang J, Han Y, Wang D. Co-expression modules construction by integrating genetic and network analysis to characterize genes related to mouse weight. PLoS Genet. 2006;2:1182–92.
35. Luan J, Xiu M, Zhou H, Misek DE, Zhou S, Zhou X, et al. Identification of key gene modules in human osteosarcoma by co-expression analysis weighted gene co-expression network analysis (WGCNA). J Cell Biochem. 2017;118:3953–9.
36. Song W-M, Zhang B. WGCNA application to proteomic and metabolomic data analysis, 2017. p. 135–58.
37. Song W-M, Zhang B. Multiscale Embedded Gene Co-expression Network Analysis. Wang E, editor. PLoS Comput Biol. 2015;11:e1004574.
38. Bastian M, Heymann S, Jacomy M. Gephi: an open source software for exploring and manipulating networks. Third Int AAAI Conf Weblogs Soc Media. 2009.
39. Marzdokht M, Marycz K, Tomaszewski KA, Kornicka K, Henry BM. The influence of aging on the regenerative potential of human adipose derived mesenchymal stem cells. Stem Cells Int. 2016;2016:1–15.
40. Ma N, Qiao C, Zhang W, Luo H, Zhang X, Liu D, et al. Original Research: Adipose-derived stem cells from younger donors, but not aging donors, inspire the host self-healing capability through its secretome. Exp Biol Med. 2017;242:68–79.
41. Liang X, Ding Y, Zhang Y, Tse HF, Liaon Q. Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives. Cell Transplant. 2014;23:1045–59.
42. Hebert TL, Wu X, Yu G, Goh BC, Halvorsen Y-D, Wang Z, et al. Culture effects of epidermal growth factor (EGF) and basic fibroblast growth factor
(bFGF) on cryopreserved human adipose-derived stromal/stem cell proliferation and adipogenesis. J Tissue Eng Regen Med. 2009;3:533–61.

42. Shevchenko EK, Makarevich PT, Tsokolava ZI, Boldyrev MA, Sysoeva YV, Tkachuk VA, et al. Transplantation of modified human adipose derived stromal cells expressing VEGF165 results in more efficient angiogenic response in ischemic skeletal muscle. J Transl Med. 2013;11:138.

43. Herrmann JL, Albaranell AM, Weil BR, Manukyan MC, Pouyer JA, Brewster BJ, et al. Optimizing stem cell function for the treatment of ischemic heart disease. J Surg Res. 2011;166:138–45.

44. Tsiamis AC, Morris PN, Marron MB, Brindle NPJ. Vascular endothelial growth factor modulates the Tie-2-Tie-1 receptor complex. Microvasc Res. 2002;63:149–58.

45. Lee D-H, Xu J, Fueyo J, Alonso MM, Liu D, Martin V, et al. Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating HIF-1 alpha levels in gliomas. Oncogene. 2008;27:1310–4.

46. Strickland LA, Jubbe AM, Hongo J-A, Zhong F, Bunrick J, Fu L, et al. Plasmalemmal vesicle-associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor-A (VEGF). J Pathol. 2005;206:466–75.

47. Savant S, La Porta S, Budnik A, Busch K, Tisch N, et al. The orphan receptor Tie1 controls angiogenesis and vascular remodelling by differentially regulating Tie2 in tip and stalk cells. Cell Rep. 2015;12:761–73.

48. Patan S. Tie1 and Tie2 receptor tyrosine kinases inversely regulate embryonic angiogenesis by the mechanism of intussusceptive microvascular growth. Microvasc Res. 1998;56:1–21.

49. Sato TN, Tozawa Y, Deutsch U, Wolfburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 1995;376:70–4.

50. Holash J, Misonouperie PC, Compton D, Boland P, Alexander CR, Zaggad D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietin and VEGF. Science. 1999;284:1994–8.

51. Yu Q, Stamenkovic I. Angiopoietin-2 is implicated in the regulation of tumor angiogenesis. Am J Pathol. 2001;158:553–70.

52. Nishigaki A, Okada H, Tsuzuki T, Cho H, Yasuda K, Kanzaki H. Angiopoietin 1 and angiopoietin 2 in follicular fluid of women undergoing a long protocol. Fertil Steril. 2011;96:1378–83.

53. Winiewska-Kruk J, Van Der Wijk AE, Van Veen HA, Gorgels TGMF, Vogels IMC, Vansteeg D, et al. Plasmalemma vesicle-associated protein has a key role in blood-retinal barrier loss. Am J Pathol. 2016;186:1044–54.

54. Canon-Walter EB, Hampton J, Shue E, Geynisman DM, Pillai PK, Sathamoorthy R, et al. Plasmalemmal vesicle associated protein-1 is a novel marker implicated in brain tumor angiogenesis. Clin Cancer Res. 2005;11:7643–50.

55. Dickson KA, Kang D-K, Kwon YS, Kim JC, Leland PA, Kim B-M, et al. Ribonuclease inhibitor regulates neovascularization by human angiogenin. Biochemistry. 2009;48:3804–6.

56. Fischer S, Nishio M, Dadkhahi S, Makarevich PI, Tsokolaeva ZI, Boldyrev MA, et al. Expression and localization of vascular ribonucleases in endothelial cells. Thromb Haemost. 2011;105:345–55.

57. Murdoch C, Tazzyman S, Webster S, Lewis CE. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol. 2007;178:7405–11.

58. Figueroa-Vega N, Alfonso-Pérez M, Cuesta-Mateos C, Sánchez-Madrid F, Moreno-Otero R, González-Amaro R, et al. Tie-2 is overexpressed by monocytes in autoimmune thyroid disorders and participates in their recruitment to the thyroid gland. J Clin Endocrinol Metab. 2009;94:2626–33.

59. Coffelt SB, Chen Y-Y, Mathuna M, Welford AF, Tal AO, Scholz A, et al. Angiopoietin 2 stimulates Tie2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. J Immunol. 2011;186:4183–90.

60. Wojcik E, Cantithers LM, Cantithers MD. Characterization of epithelial V-like antigen in human choroid plexus epithelial cells: potential role in CNS immune surveillance. Neurosci Lett. 2011;495:115–20.

61. DeMonte L, Porcellini S, Toffi E, Schindel J, Gordon J, Depreter M, et al. EVA regulates thymic stromal organisation and early thymocyte development. Biochem Biophys Res Commun. 2007;356:334–40.

62. Keshchinskij J, Hentitimen T, Auvinen K, Karkkis M, Salmi M, Jaakinen S. The prototype endothelial marker PAL-E is a leukocyte trafficking molecule. Blood. 2009;114:478–84.

63. Kang M-L, Kim E-A, Jeong S-Y, Im G-H. Angiopoietin-2 enhances osteogenic differentiation of bone marrow stromal cells. J Cell Biochem. 2017;118:2896–908.

64. Ohtsu N, Nakatani Y, Yamashita D, Ohue S, Ohnishi T, Kondo T. Eva1 maintains the stem-like character of glioblastoma-initiating cells by activating the noncanonical NF-κB signaling pathway. Cancer Res. 2016;76:171–81.

65. Califarelli A, Diel P, Vollmer G. Effect of phytoestrogens on gene expression of carbonic anhydrase II in rat uterus and liver. J Steroid Biochem Mol Biol. 2005;97:251–6.

66. Härkönen PL, Mäkelä SI, Valve EM, Karhukorpi EK, Väänänen HK. Differential regulation of carbonic anhydrase II by androgen and estrogen in dorsal and lateral prostate of the rat. Endocrinology. 1991;128:2319–27.

67. Lelkeni P, Hentitimen TA, Laalata-Leinonen T, Taalmanen J, Väänänen HK. Carboxy anhydrase II is primarily involved in mouse osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca2++. Exp Cell Res. 1998;242:128–37.

68. Cox-York KA, Erickson CB, Pereira RI, Bessesen DH, Van Pelt RE. Region-specific effects of oestradiol on adipose-derived stem cell differentiation in post-menopausal women. J Cell Mol Med. 2017;11:677–84.

69. Zamboni M, Armellini F, Milani MP, De Marchi M, Todesco T, Robb R, et al. Body fat distribution in pre- and post-menopausal women: metabolic and anthropometric variables and their inter-relationships. Int J Obes Relat Metab Disord. 1992;16:495–504.

70. Garaulet M, Pérez-Llamás F, Baraza JC, García-Prieto MD, Fardy PS, Tébar FJ, et al. Body fat distribution in pre- and post-menopausal women: metabolic and anthropometric variables. J Nutr Health Aging. 2002;6:123–6.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.